A STUDY OF THE METABOLISM OF VITAMIN D IN PATIENTS WITH RENAL CELL CARCINOMA
With Special Reference to Serum Concentration of 1α, 25-(OH)2D and its Clinical Significance
1991 Volume 82 Issue 6 Pages 890-899
Details
1991 Volume 82 Issue 6 Pages 890-899
Recently it has been known that the active form of vitamin D, 1α, 25-dihydroxyvitamin D (1α, 25-(OH)2D), plays some immunological roles in controlling cell differenciation and carcinogenesis. Moreover, 1α, 25-(OH)2D is said to have some effects in the changes of several numbers of oncogenes.
In this study, the serum concentrations of 1α, 25(OH)2D and 25-hydroxyvitamin D (25-(OH)2D) were measured in 30 patients with renal cell carcinoma. The two vitamin D metabolites were separated and purified using high performance liquid chromatography, and each fraction was subjected to competitive protein binding assay using vitamin D deficient rat serum for 25-(OH)2D and chick embryo intestinal receptors for 1α, 25-(OH)2D as the binder.
The average concentration of serum 1α, 25-(OH)2D was 28.9±5.2pg/ml for controls whereas the average in patients with renal cell carcinoma was 19.7±5.9pg/ml. The concentration of 1α, 25-(OH)2D was significantly lower in the patients with renal cell carcinoma compared to in the controls (p<0.01). The average concentrations of serum 25-(OH)2D had no significant differences between the two groups.
Comparison between the stage I+II and stage III+IV, T1+T2 and T3+T4, rapid type and slow type groups showed that the average serum 1α, 25-(OH)2D concentrations was significantly lower in the stage III+IV, T3+T4, and rapid type groups compared to the other groups (p<0.01, p<0.05, p<0.01). And besides there were no significant correlations between the concentration of serum 1α, 25-(OH)2D and creatinine clearance in patients with renal cell carcinoma.
Taken together, it is suggested that the serum concentration of 1α, 25-(OH)2D is in some way correlated with the progression of renal cell carcinoma.
